WuXi PharmaTech (WX) Tops Q4 EPS by 2c, FY Guidance Falls Short
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results
March 5, 2015 4:30 PM ESTSHANGHAI, March 5, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the fourth quarter and full year of 2014.Â
Fourth-Quarter 2014 Highlights
Net Revenues Increased 21.3% Year Over Year to $190.6 Million Laboratory Services Net Revenues Grew 17.7% Year Over Year to $140.5 Million Manufacturing Services Net Revenues Increased 32.8% Year Over Year to $50.1 Million GAAP Diluted Earnings Per... More